Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.670
+0.010 (0.60%)
At close: Jul 8, 2026, 4:00 PM EDT
1.655
-0.015 (-0.90%)
After-hours: Jul 8, 2026, 5:36 PM EDT
Entera Bio Revenue
In the year 2025, Entera Bio had annual revenue of $42.00K, down -76.80%.
Revenue (ttm)
$42.00K
Revenue Growth
-76.80%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
22
Market Cap
82.31M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.00K | -139.00K | -76.80% |
| Dec 31, 2024 | 181.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
| Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
| Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
| Dec 31, 2019 | 236.00K | -264.00K | -52.80% |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 150.71M |
| Champions Oncology | 57.95M |
| Pelthos Therapeutics | 27.70M |
| Rani Therapeutics Holdings | 3.17M |
| Rallybio | 858.00K |
| iBio, Inc. | 300.00K |
ENTX News
- 15 days ago - Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market - GlobeNewsWire
- 16 days ago - Entera Bio gets FDA feedback on registrational protocol for EB613 - TheFly
- 16 days ago - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis - GlobeNewsWire
- 22 days ago - Entera Bio and Opko Health present preclinical data for oral peptides - TheFly
- 22 days ago - Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 - GlobeNewsWire
- 23 days ago - ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) - GlobeNewsWire
- 5 weeks ago - Entera Bio Proxy statement: Proxy filing - Filings
- 5 weeks ago - Entera Bio Proxy statement: Proxy filing - Filings